JP2006513139A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006513139A5 JP2006513139A5 JP2004519544A JP2004519544A JP2006513139A5 JP 2006513139 A5 JP2006513139 A5 JP 2006513139A5 JP 2004519544 A JP2004519544 A JP 2004519544A JP 2004519544 A JP2004519544 A JP 2004519544A JP 2006513139 A5 JP2006513139 A5 JP 2006513139A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- aerosol
- aerosol formulation
- formulation according
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2002/021335 WO2003077834A2 (en) | 2002-03-15 | 2002-07-03 | Central airway administration for systemic delivery of therapeutics |
| PCT/US2003/014428 WO2004004798A2 (en) | 2002-07-03 | 2003-05-09 | Central airway administration for systemic delivery of therapeutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006513139A JP2006513139A (ja) | 2006-04-20 |
| JP2006513139A5 true JP2006513139A5 (https=) | 2006-09-14 |
Family
ID=30113575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004519544A Ceased JP2006513139A (ja) | 2002-07-03 | 2003-05-09 | 治療薬の全身性送達のための中央部気道投与 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1539246A4 (https=) |
| JP (1) | JP2006513139A (https=) |
| AU (1) | AU2003232081B2 (https=) |
| CA (1) | CA2491129A1 (https=) |
| WO (1) | WO2004004798A2 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| PT1624891E (pt) | 2003-05-06 | 2010-01-05 | Syntonix Pharmaceuticals Inc | Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US8007805B2 (en) | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
| US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| JP2008504012A (ja) * | 2004-01-28 | 2008-02-14 | シントニックス・ファーマシューティカルズ・インコーポレーテッド | 不妊治療のためのへテロ二量体卵胞刺激ホルモン−Ｆｃ（ＦＳＨ−Ｆｃ）融合タンパク質 |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| US8435517B2 (en) | 2008-09-17 | 2013-05-07 | Xencor, Inc. | Compositions and methods for treating IgE-mediated disorders |
| US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
| CN103172731A (zh) | 2004-07-15 | 2013-06-26 | 赞科股份有限公司 | 优化的Fc变体 |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| DK1817340T3 (da) | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
| WO2007008943A2 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
| WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| WO2007044616A2 (en) | 2005-10-06 | 2007-04-19 | Xencor, Inc. | Optimized anti-cd30 antibodies |
| US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
| PL2383297T3 (pl) | 2006-08-14 | 2013-06-28 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| WO2008036688A2 (en) | 2006-09-18 | 2008-03-27 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
| GB0707208D0 (en) * | 2007-04-13 | 2007-05-23 | Istituto Superiore Di Sanito | Novel disease treatments |
| CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| US20090110679A1 (en) * | 2007-07-13 | 2009-04-30 | Luk-Chiu Li | Methods and compositions for pulmonary administration of a TNFa inhibitor |
| WO2009012600A1 (en) | 2007-07-26 | 2009-01-29 | Novagen Holding Corporation | Fusion proteins |
| JP5314033B2 (ja) * | 2007-10-22 | 2013-10-16 | メルク セローノ ソシエテ アノニム | 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ |
| TWI543768B (zh) * | 2007-11-30 | 2016-08-01 | 艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
| RU2529951C2 (ru) | 2007-12-26 | 2014-10-10 | Ксенкор, Инк. | ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn |
| US12492253B1 (en) | 2008-02-25 | 2025-12-09 | Xencor, Inc. | Anti-human C5 antibodies |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
| CN102492039B (zh) * | 2011-11-21 | 2015-03-11 | 无锡天演生物技术有限公司 | 全人源抗人her2单抗 |
| LT3495387T (lt) | 2012-07-13 | 2021-11-25 | Roche Glycart Ag | Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti |
| US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| CN106132398A (zh) | 2014-04-03 | 2016-11-16 | 瑞士杰特贝林生物制品有限公司 | 免疫球蛋白的雾化 |
| US20160060360A1 (en) | 2014-07-24 | 2016-03-03 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| WO2016067252A1 (en) | 2014-10-31 | 2016-05-06 | Glaxosmithkline Intellectual Property Development Limited | Powder formulation |
| AU2016355563A1 (en) * | 2015-11-16 | 2018-06-21 | The Trustees Of The University Of Pennsylvania | Targeted delivery of therapeutic proteins bioencapsulated in plant cells to cell types of interest for the treatment of disease |
| EP3468997B1 (en) | 2016-06-08 | 2023-09-13 | Xencor, Inc. | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
| EP3873519A1 (en) | 2018-10-29 | 2021-09-08 | F. Hoffmann-La Roche AG | Antibody formulation |
| CA3228786A1 (en) * | 2021-08-25 | 2023-03-02 | Ibio, Inc. | Anti-cd25 antibody |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8921123D0 (en) * | 1989-09-19 | 1989-11-08 | Millar Ann B | Treatment of ards |
| JPH05963A (ja) * | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| EP1323346B1 (en) * | 1995-01-17 | 2006-06-28 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6030613A (en) * | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| MA25590A1 (fr) * | 1998-09-14 | 2002-12-31 | Inhale Therapeutic Syst | Agent actif de delivraison de poudre seche |
| US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
| US6858199B1 (en) * | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
| WO2001059142A1 (en) * | 2000-02-09 | 2001-08-16 | Medimmune, Inc. | Antibody gene therapy with adeno-associated viral vectors |
| MXPA02009485A (es) * | 2000-03-31 | 2003-03-10 | Kirin Brewery | Preparacion en polvo para administracion a traves de la mucosa, que comprende un farmaco de alto peso molecular y que muestra una estabilidad mejorada en almacenamiento. |
| EP2412384A1 (en) * | 2000-11-28 | 2012-02-01 | MedImmune, LLC | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| SE0102067D0 (sv) * | 2001-06-11 | 2001-06-11 | A & Science Invest Ab | Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation |
| AU2002316574B2 (en) * | 2002-03-15 | 2008-05-01 | Brandeis University | Central airway administration for systemic delivery of therapeutics |
-
2003
- 2003-05-09 AU AU2003232081A patent/AU2003232081B2/en not_active Ceased
- 2003-05-09 CA CA002491129A patent/CA2491129A1/en not_active Abandoned
- 2003-05-09 JP JP2004519544A patent/JP2006513139A/ja not_active Ceased
- 2003-05-09 WO PCT/US2003/014428 patent/WO2004004798A2/en not_active Ceased
- 2003-05-09 EP EP03762973A patent/EP1539246A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006513139A5 (https=) | ||
| Mirick et al. | A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words | |
| US20230220102A1 (en) | Cd25 antibodies | |
| JP2020039360A5 (https=) | ||
| JP2005516044A5 (https=) | ||
| HRP20160632T1 (hr) | Vezivne molekule specifične za rsv i sredstva za njihovu proizvodnju | |
| CN102046654A (zh) | 针对甲型流感病毒h5n1株系的抗体 | |
| JP2018512170A5 (https=) | ||
| WO2006050166A3 (en) | Methods of preventing and treating rsv infections and related conditions | |
| NZ597996A (en) | Antibodies against human respiratory syncytial virus (rsv) and methods of use | |
| HRP20160485T1 (hr) | Anti-mezotelinska protutijela i njihova uporaba | |
| HRP20150641T1 (hr) | Anti -cd38 humana antitijela i njihove uporabe | |
| WO2005090405A1 (ja) | インターロイキン－６受容体に対するヒト型化抗体のサブタイプ | |
| CN101679513A (zh) | 用于治疗呼吸道合胞病毒感染的重组抗体 | |
| JP2009509538A5 (https=) | ||
| RU2017115670A (ru) | Лечение инфекции рсв | |
| JP2008513354A5 (https=) | ||
| JP2011006464A (ja) | 喘息の治療における抗−ＴＮＦα抗体 | |
| CN114504651A (zh) | 抗体、用途和方法 | |
| JP2020533965A5 (https=) | ||
| JP2017524359A (ja) | Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー | |
| JP2017524359A5 (https=) | ||
| CN102292351A (zh) | 结合il-13的配体 | |
| JP2013519690A5 (https=) | ||
| WO2013076702A3 (es) | Anticuerpos monoclonales específicos para el antígeno m2-1 del virus respiratorio sincicial (vrs) |